title: Serum levels of angiogenic molecules in autoimmune thyroid diseases and their correlation with laboratory and clinical features.
abstract: BACKGROUND
  Because angiogenesis has a role in the pathogenesis of inflammatory conditions, we studied angiogenesis soluble markers in autoimmune thyroid diseases.
  
  
  OBJECTIVE
  The aim of the study was to measure concentrations of angiopoietins, Tie-2, and vascular endothelial growth factor in sera from autoimmune thyroid disease patients.
  
  
  METHODS
  Soluble Tie-2 (sTie-2), angiopoietin-1, angiopoietin-2, and vascular endothelial growth factor were quantified by ELISA in sera from 44 untreated Graves' disease (GD) patients, 25 untreated Hashimoto's thyroiditis (HT) patients, 13 non-GD hyperthyroid patients, and 22 age-matched controls. Subgroups of patients with active and non-active Graves' ophthalmopathy (GO) were analyzed. Correlations among these markers and clinical parameters were assessed by bivariate and multivariate analyses.
  
  
  RESULTS
  STIE-2 levels were higher in GD or HT patients compared to controls (P < 0.01). In addition, serum Ang-2 concentrations were higher in untreated GD patients compared to controls, HT patients, or non-GD hyperthyroid patients (P < 0.01), and no difference was observed between HT patients and controls. Significant correlations were found between free T(4)/sTie-2 and free T(4)/Ang-2 levels (r = 0.464, P < 0.01; and r = 0.463, P < 0.01, respectively) as well as between sTie-2/anti-TSH receptor antibody (r = 0.527; P < 0.01) and sTie-2/Ang-2 (r = 0.563; P = 0.001). Furthermore, sTie-2 levels were significantly higher in patients with active GO when compared to those with inactive GO (P < 0.05). Interestingly, Ang-2 levels decreased significantly after treatment with antithyroid drugs (P < 0.01).
  
  
  CONCLUSIONS
  Ang-2 and sTie-2 could participate in the pathogenesis of GD and potentially be used as markers of GO activity. Antithyroid drugs affect the angiogenic pattern in GD.
authors.affiliation: Department of Immunology, School of Medicine, Universidad Autónoma de San Luis Potosí, San Luis Potosí, México.
authors.forename: Nicté
authors.initials: N
authors.lastname: Figueroa-Vega
authors.forename: Paloma
authors.initials: P
authors.lastname: Sanz-Cameno
authors.forename: Ricardo
authors.initials: R
authors.lastname: Moreno-Otero
authors.forename: Francisco
authors.initials: F
authors.lastname: Sánchez-Madrid
authors.forename: Roberto
authors.initials: R
authors.lastname: González-Amaro
authors.forename: Mónica
authors.initials: M
authors.lastname: Marazuela
mesh_terms: D000328:Adult; D042683:Angiopoietin-1 / Q000097:blood; D042702:Angiopoietin-2 / Q000097:blood; D005260:Female; D049970:Graves Ophthalmopathy / Q000097:blood; D050031:Hashimoto Disease / Q000097:blood; D006801:Humans; D008297:Male; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000097:blood; D042787:Receptor, TIE-2 / Q000097:blood*; D013967:Thyroiditis, Autoimmune / Q000097:blood*; D042461:Vascular Endothelial Growth Factor A / Q000097:blood*
chemical_list: C467630:ANGPT1 protein, human; D042683:Angiopoietin-1; D042702:Angiopoietin-2; D042461:Vascular Endothelial Growth Factor A; D042787:Receptor, TIE-2